drugset / Trial / NCT07265466

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

NCT07265466

Phase 1 Recruiting 96 enrolled Onconic Therapeutics Inc.
RandomizedFactorialOpen-labelTreatment

Summary

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Timeline

Start
2025-11-17
Primary completion
2026-03-30
Completion
2026-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule
Subject Aspirin Small molecule
Subject Atorvastatin Small molecule
Subject Clopidogrel Small molecule
Subject JP-1366 Unknown

Indications

No indication recorded.